[Autonomic cardiovascular regulation in patients with tics and Tourette syndrome].
Autonomic cardiovascular regulation has been assessed in patients aged 4-15 years with Tourette syndrome (n = 22) and other tic disorders (n = 48). Symptom significance was estimated by a number of hyperkinetic episodes per 20 minutes, tic scale and variants of the disease course. The functional condition of autonomic nervous system was studied clinically and using spectral analysis of heart rate variability in both upright and supine positions. Negative correlation between the ratio of sympathetic and vagus influences and severity of the disease was found: the severer were tic symptoms, the stronger was a trend to vagotonia (beta = -0.36; p < 0.0025; F > 4.0). In orthostatic test, patients with Tourette syndrome demonstrated an unfavorable hypersympathicotonic type of cardiovascular system reaction. Patients were treated during 4 weeks with glycinum (0.2 +/- 0.1 mg/day), phenibutum (0.5 +/- 0.25 mg/day), clonazepam (1.5 +/- 0.5 mg/day), tiapride (200 +/- 100 mg/day), haloperidol (1-1.5 mg/day), rispolept (2 mg/day). There was no negative effect of the drugs on heart rate variability. On the contrary, the therapy reduced hyperkinetic symptoms and corrected autonomic influences on the sinus rhythm. It is suggested that changes in autonomic cardiovascular regulation might be of secondary character and do not need any special correction.
Zykov
V P
VP
Komarova
I B
IB
Nazarova
E K
EK
Begasheva
O I
OI
Kabanova
S A
SA
D018726:Anti-Dyskinesia Agents / Q000494:pharmacology / Q000627:therapeutic use; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D002648:Child; D002998:Clonazepam / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005998:Glycine / Q000494:pharmacology / Q000627:therapeutic use; D018684:Glycine Agents / Q000494:pharmacology / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D013976:Tiapamil Hydrochloride / Q000494:pharmacology / Q000627:therapeutic use; D020323:Tics / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D005879:Tourette Syndrome / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D020421:Vagus Nerve Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D018726:Anti-Dyskinesia Agents; D000927:Anticonvulsants; D018684:Glycine Agents; D005680:gamma-Aminobutyric Acid; D002998:Clonazepam; C008842:4-amino-3-phenylbutyric acid; D005998:Glycine; D013976:Tiapamil Hydrochloride